Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

Irwin Walker, MBBS, Kirk R. Schultz, MD, Cynthia L. Toze, MD FRCPC, Holly Margaret Kerr, RN, BSN, John Moore, MD, David Szwajcer, MD FRCPC, Stephen Ronan Foley, MD FRCPC, John Kuruvilla, MD FRCPC, Tony Panzarella, M.Sc, Félix Couture, MD, Jean Roy, MD, Stephen Couban, MD FRCPC, Gerald Devins, PhD, Gizelle Popradi, FRCPC, MD, Stephanie J. Lee, MD MPH, Jason Tay, MD MSc, FRCPC, Thomas J. Nevill, MD FRCPC, Mohamed Elemary, MD MSc,PhD, Genevieve Gallagher, MD FRCPC

Blood (2014) 124 (21): 38.

https://doi.org/10.1182/blood.V124.21.38.38

Published: 2014

Journal Articles

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Fotios V. Michelis, MDPhD, Rouslan Kotchetkov, MD, Aamir Azeem, Rebecca M. Grunwald, Jieun Uhm, MD, Naheed Alam, MBBS, MD, Anna Lambie, NP, Laura McGillis, NP, David Loach, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 1237.

https://doi.org/10.1182/blood.V124.21.1237.1237

Published: 2014

Journal Articles

Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience

Fotios V. Michelis, MDPhD, Rouslan Kotchetkov, MD, Rebecca M. Grunwald, Aamir Azeem, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Laura McGillis, NP, Anna Lambie, NP, David Loach, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 1179.

https://doi.org/10.1182/blood.V124.21.1179.1179

Published: 2014

Journal Articles

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

Mohamed Shanavas, MD FRACP, FRCPA, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Eshetu G Atenafu, MSc, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Matthew Seftel, MRCP, FRCPC, MPH, Vikas Gupta, MD MRCP, FRCPath, Dennis Kim, MD PhD

Blood (2014) 124 (21): 5927.

https://doi.org/10.1182/blood.V124.21.5927.5927

Published: 2014

Journal Articles

Lymphocyte Recovery At Day 28 Post-Transplant Is Predictive Of Relapse In Patients With Acute Myeloid Leukemia Transplanted With Peripheral Blood Stem Cell Grafts

Fotios V. Michelis, MD, PhD, Hans A. Messner, MD, PhD, Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Jeffrey H. Lipton, MD, PhD, Dennis Dong Hwan Kim, MD, PhD

Blood (2013) 122 (21): 3393.

https://doi.org/10.1182/blood.V122.21.3393.3393

Published: 2013

Journal Articles

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

Blood (2013) 122 (21): 1942.

https://doi.org/10.1182/blood.V122.21.1942.1942

Published: 2013

Journal Articles

A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation

Mohamed Shanavas, MD, FRACP, FRCPA, Hans A. Messner, MD, PhD, Suzanne Kamel-Reid, PhD, Eshetu G Atenafu, MSc, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Dennis Dong Hwan Kim, MD, PhD, Jieun Uhm, MD, Anna Lambie, NP, Laura Ellis, NP, MN, RN (EC), Jeffrey H. Lipton, MD, PhD

Blood (2013) 122 (21): 5501.

https://doi.org/10.1182/blood.V122.21.5501.5501

Published: 2013

Journal Articles

The Modified Pre-Transplant EBMT Risk Score Is Superior To The HCT-CI Score In Predicting Overall Survival and Non-Relapse Mortality After Allogeneic Hematopoietic Cell Transplantation In Patients With Acute Myeloid Leukemia

Fotios V. Michelis, MD, PhD, Hans A. Messner, MD, PhD, Jieun Uhm, MD, Anna Lambie, NP, Laura McGillis, NP, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Jeffrey H. Lipton, MD, PhD, Dennis Dong Hwan Kim, MD, PhD

Blood (2013) 122 (21): 2153.

https://doi.org/10.1182/blood.V122.21.2153.2153

Published: 2013

Journal Articles

The Risk Of BK Virus Haemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation Is Increased With Myeloablative Conditioning, CMV Viremia and Acute Gvhd

Jieun Uhm, MD, Nada Hamad, MBBS Hons, FRACP, FRCPA, Mohamed Shanavas, MD, FRACP, FRCPA, Fotios V. Michelis, MD, PhD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dennis Kim, MD

Blood (2013) 122 (21): 3289.

https://doi.org/10.1182/blood.V122.21.3289.3289

Published: 2013

Journal Articles

Risk Factors For Chronic Eye and Mouth GVHD In Unrelated Hematopoietic Cell Transplantation: T Cell Depletion Is The Only Risk Factor Identified and Appears To Be Favorable

Mohamed Shanavas, MD, FRACP, FRCPA, Nada Hamad, MBBS Hons, FRACP, FRCPA, Fotios V. Michelis, MD, PhD, Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD, Dennis Dong Hwan Kim, MD, PhD

Blood (2013) 122 (21): 4601.

https://doi.org/10.1182/blood.V122.21.4601.4601

Published: 2013

Journal Articles

Steroid Failure At Day 28 After Acute Graft-Versus-Host Disease Treatment and Long-Term Outcomes Following Allogeneic Transplantation: Adverse Impact On Survival and Non-Relapse Mortality But No Increasing Risk Of Relapse

Joon Ho Moon, M.D., Ph.D., Sang Kyun Sohn, MD, PhD, Naheed Alam, MBBS, Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, M.D./Ph.D, John Kuruvilla, MD, FRCPC, Dennis Dong Hwan Kim, MD, PhD

Blood (2013) 122 (21): 2066.

https://doi.org/10.1182/blood.V122.21.2066.2066

Published: 2013

Journal Articles

The Risk of Organ Specific Graft-Versus-Host Disease Can Be Predicted by the Multiple Single Nucleotide Polymorphism Based Predictive Models.

Dennis Dong Hwan Kim, MD, PhD, Hong-Hee Won, Wei Xu, Ph.D., Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, John Kuruvilla, MD, FRCPC, Hans A. Messner, MD, PhD, Jeffrey H. Lipton, MD, PhD

Blood (2012) 120 (21): 3056.

https://doi.org/10.1182/blood.V120.21.3056.3056

Published: 2012

Journal Articles

The Benefit of Allogeneic Hematopoietic Cell Transplantation in Older Patients with Acute Myeloid Leukemia Is Restricted to Those in First Complete Remission At the Time of Transplantation.

Fotios V. Michelis, MD, PhD, Hans A. Messner, MD, PhD, Eshetu G Atenafu, MSc, Dennis Dong Hwan Kim, MD, PhD, John Kuruvilla, MD, FRCPC, Jeffrey H. Lipton, MD, PhD, Jieun Uhm, MD, David Loach, MD, Vikas Gupta, MD, FRCP, FRCPath

Blood (2012) 120 (21): 3097.

https://doi.org/10.1182/blood.V120.21.3097.3097

Published: 2012

Journal Articles

Independent Validation of Chronic Graft-Versus-Host Disease (GVHD) Grading System Proposed by the NIH Consensus Criteria in Terms of Prognostic Stratification of the Patients Developed Chronic Gvhd

Joon Ho Moon, MD, Sang Kyun Sohn, MD, Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, M.D./Ph.D, John Kuruvilla, MD, FRCPC, Dennis Dong Hwan Kim, MD, PhD

Blood (2012) 120 (21): 1946.

https://doi.org/10.1182/blood.V120.21.1946.1946

Published: 2012

Journal Articles

Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd

Joon Ho Moon, MD, Sang Kyun Sohn, MD, Jieun Uhm, MD, Vikas Gupta, MD, FRCP, FRCPath, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, M.D./Ph.D, John Kuruvilla, MD, FRCPC, Dennis Dong Hwan Kim, MD, PhD

Blood (2012) 120 (21): 4184.

https://doi.org/10.1182/blood.V120.21.4184.4184

Published: 2012

Journal Articles

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

Blood (2012) 120 (21): 745.

https://doi.org/10.1182/blood.V120.21.745.745

Published: 2012

Journal Articles

A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis

Blood (2012) 120 (21): 1586.

https://doi.org/10.1182/blood.V120.21.1586.1586

Published: 2012

Journal Articles

Allogeneic Stem Cell Transplantation Is Associated with Prolonged Disease Control in Chemosensitive Aggressive Histology Lymphoma Patients When Done Early

Auro Viswabandya, MD, DM, Tony Panzarella, MSc, Dennis Dong Hwan Kim, Vikas Gupta, MD, FRCP, FRCPath, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, PhD, John Kuruvilla, MD, FRCPC

Blood (2011) 118 (21): 4525.

https://doi.org/10.1182/blood.V118.21.4525.4525

Published: 2011

Journal Articles

Incidence, Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation

Kit Man Wong, Eshetu G Atenafu, Dennis Dong Hwan Kim, John Kuruvilla, MD, FRCPC, Jeffrey H. Lipton, MD, PhD, Hans A. Messner, PhD, Vikas Gupta, MD, FRCP, FRCPath

Blood (2011) 118 (21): 1951.

https://doi.org/10.1182/blood.V118.21.1951.1951

Published: 2011

Journal Articles

Incidence and Predictors of Bleomycin Pulmonary Toxicity in Hodgkin Lymphoma (HL) Patients Treated with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD),

Haowei (Linda) Sun, MD, Eshetu Atenafu, MSc, Richard Tsang, MD, Vishal Kukreti, MD, FRCPC, Michael Crump, MD, FRCPC, John Kuruvilla, MD, FRCPC

Blood (2011) 118 (21): 3643.

https://doi.org/10.1182/blood.V118.21.3643.3643

Published: 2011

NARROW

Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: A Single Center Experience

Evidence of Effect Modification of Graft-Versus-Leukemia Effect of Cytomegalovirus By Alemtuzumab in Myeloid Malignancies Undergoing Unrelated Donor Transplantation

Lymphocyte Recovery At Day 28 Post-Transplant Is Predictive Of Relapse In Patients With Acute Myeloid Leukemia Transplanted With Peripheral Blood Stem Cell Grafts

Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom’s Macroglobulinemia (WM)

A Comparison Of Long-Term Outcomes Of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors In CML Patients Relapsed After Allogeneic Hemopoietic Stem Cell Transplantation

The Modified Pre-Transplant EBMT Risk Score Is Superior To The HCT-CI Score In Predicting Overall Survival and Non-Relapse Mortality After Allogeneic Hematopoietic Cell Transplantation In Patients With Acute Myeloid Leukemia

The Risk Of BK Virus Haemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation Is Increased With Myeloablative Conditioning, CMV Viremia and Acute Gvhd

Risk Factors For Chronic Eye and Mouth GVHD In Unrelated Hematopoietic Cell Transplantation: T Cell Depletion Is The Only Risk Factor Identified and Appears To Be Favorable

Steroid Failure At Day 28 After Acute Graft-Versus-Host Disease Treatment and Long-Term Outcomes Following Allogeneic Transplantation: Adverse Impact On Survival and Non-Relapse Mortality But No Increasing Risk Of Relapse

The Risk of Organ Specific Graft-Versus-Host Disease Can Be Predicted by the Multiple Single Nucleotide Polymorphism Based Predictive Models.

The Benefit of Allogeneic Hematopoietic Cell Transplantation in Older Patients with Acute Myeloid Leukemia Is Restricted to Those in First Complete Remission At the Time of Transplantation.

Independent Validation of Chronic Graft-Versus-Host Disease (GVHD) Grading System Proposed by the NIH Consensus Criteria in Terms of Prognostic Stratification of the Patients Developed Chronic Gvhd

Prognostic Power of Chronic Gvhd Risk Score Model by Ibmtr Can Be Improved with Addition of Absolute Lymphocyte Counts and Eosinophil Counts At the Onset of Chronic Gvhd

Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12

A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis

Allogeneic Stem Cell Transplantation Is Associated with Prolonged Disease Control in Chemosensitive Aggressive Histology Lymphoma Patients When Done Early

Incidence, Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation

Incidence and Predictors of Bleomycin Pulmonary Toxicity in Hodgkin Lymphoma (HL) Patients Treated with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD),

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only